Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venlafaxine versus atomoxetine in children with ADHD
IRCT20180502039508N3Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of venlafaxine and atomoxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Severity of ADHD symptoms, Anxiety and 1 more. Started Sep 2025; status: completed.
02
Drugs
venlafaxineatomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20180502039508N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180502039508N3.